课题基金 / 基金详情

BG9273 (LFA3/IGG1 FUSION PROTEIN) IN PATIENTS WITH CHRONIC PSORIASIS

BG9273 (LFA3/IGG1 FUSION PROTEIN) IN PATIENTS WITH CHRONIC PSORIASIS
BG9273（LFA3/IGG1 融合蛋白）在慢性银屑病患者中的应用
批准号：
6274783
负责人：
Sewon Kang
金额：
$2.15万
依托单位：
UNIVERSITY OF MICHIGAN AT ANN ARBOR
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-12-01 至 1998-11-30
来源：
https://reporter.nih.gov/project-details/6274783
关键词：
chimeric proteins clinical research dosage drug adverse effect drug screening /evaluation human subject human therapy evaluation immunoglobulin G intravenous administration leukocyte adhesion molecules pharmacokinetics psoriasis skin disorder chemotherapy

项目摘要

项目成果

Sewon Kang的其他基金

相似基金

相关文献

中文摘要
翻译
这是一个二期多中心，随机，双盲，多剂量，
英文摘要
This is a Phase II multicenter, randomized, double-blind, multiple-dose, dose-escalation study to evaluate the tolerability, pharmacokinetics, biological activity and efficacy of BG9273 (Biogen Inc.'s LFA-3/IgG1 Fusion Protein) when administered as multiple doses to patients with moderate to severe, chronic psoriasis. Each patient will receive one 30 minute intravenous infusion of BG9273 every week for a total of eight doses and will be assessed by clinical and laboratory examination for evidence of toxicity and biologic response.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
P3: Infrared Irradiation and Scleroderma Skin
OPEN LABEL STUDY OF TETRATHIOMOLYBDATE IN TREATMENT OF PSORIASIS VULGARIS
University of Michigan Multidisciplinary Clinical Research (RMI)
Univ of Michigan Multidisciplinary Clinical Resea**(RMI)
海外基金